Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells

Basit Öğe Kaydı
dc.contributor.authorKarabulut, B.
dc.contributor.authorErten, C.
dc.contributor.authorGul, M. K.
dc.contributor.authorCengiz, E.
dc.contributor.authorKaraca, B.
dc.contributor.authorKucukzeybek, Y.
dc.contributor.authorGorumlu, G.
dc.contributor.authorAtmaca, H.
dc.contributor.authorUzunoglu, S.
dc.contributor.authorSanli, U. A.
dc.contributor.authorBaran, Y.
dc.contributor.authorUslu, R.
dc.date.accessioned2019-10-27T20:19:23Z
dc.date.available2019-10-27T20:19:23Z
dc.date.issued2009
dc.departmentEge Üniversitesien_US
dc.description.abstractDocetaxel, a semi-synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most potent member of bisphosphonates, has shown pleiotropic anti-tumoral effects on prostate cancer cells. We have explored the possible additive/synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug refractory, PC-3 and DU-145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and DU-145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl-2 in PC-3 and DU-145 cells. In conclusion, docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer. (C) 2008 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.cellbi.2008.11.011en_US
dc.identifier.endpage246en_US
dc.identifier.issn1065-6995
dc.identifier.issn1095-8355
dc.identifier.issue2en_US
dc.identifier.pmid19103299en_US
dc.identifier.startpage239en_US
dc.identifier.urihttps://doi.org/10.1016/j.cellbi.2008.11.011
dc.identifier.urihttps://hdl.handle.net/11454/41414
dc.identifier.volume33en_US
dc.identifier.wosWOS:000262980300015en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofCell Biology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProstate canceren_US
dc.subjectPC-3en_US
dc.subjectDU-145en_US
dc.subjectDocetaxelen_US
dc.subjectZoledronic aciden_US
dc.subjectBcl-2en_US
dc.titleDocetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cellsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu